Insider Buying: CSL Limited (ASX:CSL) Insider Buys A$50,012.00 in Stock

CSL Limited (ASX:CSL) insider Megan Clark acquired 200 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was bought at an average cost of A$250.06 ($159.27) per share, for a total transaction of A$50,012.00 ($31,854.78).

Megan Clark also recently made the following trade(s):

• On Wednesday, February 19th, Megan Clark bought 132 shares of CSL stock. The shares were purchased at an average price of A$264.85 ($168.69) per share, with a total value of A$34,959.94 ($22,267.48).

CSL Price Performance

The company has a quick ratio of 1.68, a current ratio of 1.86 and a debt-to-equity ratio of 64.46. The firm has a market cap of $77.43 billion, a P/E ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32.

CSL Increases Dividend

The company also recently declared a Interim dividend, which will be paid on Tuesday, April 8th. Shareholders of record on Tuesday, April 8th will be given a dividend of $2.073 per share. The ex-dividend date of this dividend is Sunday, March 9th. This represents a yield of 0.81%. This is an increase from CSL’s previous Interim dividend of $1.83. CSL’s dividend payout ratio is 50.38%.

About CSL

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.